SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination-Reference-Cited by-同舟云学术

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination

Published:2022-05 Issue:5 Volume:39 Page:110754
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Arora Prerna,Kempf Amy,Nehlmeier Inga,Graichen Luise,Winkler Martin S.,Lier Martin,Schulz Sebastian,Jäck Hans-Martin,Cossmann Anne,Stankov Metodi V.,Behrens Georg M.N.,Pöhlmann Stefan,Hoffmann Markus^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference36 articles.

1. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination;Arora;Cell Rep.,2021

2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N. Engl. J. Med.,2021

3. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon;Berger Rentsch;PLoS One,2011

4. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells;Brinkmann;PLoS One,2017

5. Distinct conformational states of SARS-CoV-2 spike protein;Cai;Science,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture;British Journal of Pharmacology;2024-04-14

2. Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants;Journal of Immunology Research;2024-01-25

3. Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population;Frontiers in Immunology;2023-07-27

4. A SARS-CoV-2: Companion Animal Transmission and Variants Classification;Pathogens;2023-05-29

5. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19;Frontiers in Bioengineering and Biotechnology;2022-11-25